N. Rosen

eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer

This paper identifies eIF4A as a key regulator of ER translation in breast cancer and shows that inhibiting eIF4A, either alone or with fulvestrant, suppresses ER expression and tumor growth in advanced ER+ breast cancer.

Tumorigenesis driven by the BRAF V600E oncoprotein requires secondary mutations that overcome its feedback inhibition of migration and invasion

This study shows that BRAFV600E mutations inhibit cell migration and invasion through feedback inhibition of RAC1, requiring secondary mutations to overcome this block and enable tumorigenesis.

Anatomic position determines oncogenic specificity in melanoma

The paper shows that anatomic position influences oncogenic specificity in melanoma by identifying position-specific gene programs that interact with oncogenes like CRKL.

Mutant-selective Degradation by BRAF-targeting PROTACs

This study develops BRAF-targeting PROTACs that degrade all BRAF mutants at sub-nanomolar concentrations while sparing wild-type RAF family members, showing in vivo efficacy and mechanistic insights.

Anti-tumor effects of an Id antagonist with no acquired resistance

This study demonstrates that AGX51, an Id antagonist, effectively inhibits tumor growth in multiple cancer models without inducing acquired resistance.